Temozolomide in aggressive and metastatic pituitary tumors: a Brazilian multicenter real-world cohort study
Authors' conclusion
In this multicenter Brazilian real-world cohort, TMZ provided high radiological and biochemical disease control with an acceptable safety profile
Study context
- Population
- Patients with aggressive/metastatic pituitary adenomas treated with temozolomide (TMZ) and followed ≥6 months, Brazilian reference centers; mean age 29.5 years, 53% female; all macroadenomas, 56% giant (>4 cm); 21 functioning, 4 metastatic; Ki-67 >3% in 73%; mean time from diagnosis to TMZ 102 months
- Participants
- 30 patients
- Outcome
- Radiological disease control rate (partial response or stable disease; RECIST 1.1)
Methodological detailsmulticenter, real-world
- Multicenter
- Real-world
Main finding
As reported in the abstract
TMZ
93.3%
Observational data: associations, not effects.
Further findings
Biochemical disease control rate, functioning tumors
- Biochemical disease control rate among functioning tumors
- 81.2%
Objective biochemical response rate (complete + partial response), functioning tumors
- Objective biochemical response rate (complete + partial response) among functioning tumors
- 68.8%
Safety
- Adverse events, most commonly nausea and myelotoxicity
- 66% of patients
Original publication
Temozolomide in aggressive and metastatic pituitary tumors: a Brazilian multicenter real-world cohort study. Pituitary. Published 27 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →